Skip to main content
JIUZHITANG CO.,LTD logo

JIUZHITANG CO.,LTD — Investor Relations & Filings

Ticker · 000989 ISIN · CNE000001394 LEI · 3003004OFW6FCZ34KN72 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,885 across all filing types
Latest filing 2019-11-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000989

About JIUZHITANG CO.,LTD

https://www.hnjzt.com

JIUZHITANG CO.,LTD. is a pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of Traditional Chinese Medicine (TCM). Established in 1650, the company is recognized as a time-honored brand with a heritage spanning over three centuries. Its core product portfolio includes a diverse range of TCM formulations, most notably Liuwei Dihuang Wan, donkey-hide gelatin (Ejiao), and various health supplements focused on chronic disease management and general wellness. The company operates modern production facilities that integrate traditional processing techniques with contemporary scientific standards and biotechnology. JIUZHITANG focuses on the modernization of TCM through clinical research and innovation, maintaining a distribution network that serves retail pharmacies and medical institutions to provide natural healthcare solutions.

Recent filings

Filing Released Lang Actions
关于并购基金的投资进展公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (1587 characters) titled as a "临时公告" (temporary announcement) regarding the investment progress of an acquisition fund related to clinical trial approvals. It provides updates on regulatory acceptance of a clinical trial application by the National Medical Products Administration (国家药品监督管理局) and discusses the impact and risks. There are no financial statements, detailed financial data, or comprehensive report content. The document is an update on a specific investment and regulatory progress, not a full report or detailed financial disclosure. It fits best as a Capital/Financing Update (CAP) because it relates to investment progress in an acquisition fund and clinical trial approval status, which impacts the company's capital and investment activities. The document is not an announcement of a report publication, nor a regulatory filing in the fallback sense, but a substantive update on financing/investment progress. Confidence is high due to clear content and context.
2019-11-19 Chinese
2019年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2019年第三季度报告' which translates to '2019 Third Quarter Report'. It contains detailed financial data including balance sheets, income statements, cash flow statements, and explanations of financial changes during the quarter. The presence of comprehensive financial metrics, management discussion on financial performance, and detailed tables of financial figures for the quarter strongly indicate this is a quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-30 Chinese
2019年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019 Third Quarter Report" of 九芝堂股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and shareholder information for the third quarter of 2019. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length (7156 characters) and content are consistent with a full quarterly report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2019
2019-10-30 Chinese
关于并购基金的投资进展公告
Capital/Financing Update Classification · 90% confidence The document is titled as a '临时公告' (temporary announcement) and is relatively short (1391 characters). It discusses the progress of an investment by the company's merger and acquisition fund in a clinical trial and publication of research results related to that investment. The document provides an update on the investment progress and risk warning but does not contain financial statements or detailed financial analysis. It is an announcement about the progress of an investment related to M&A activities but does not constitute a full M&A filing or merger communication. Given the content and length, it fits best as a Capital/Financing Update (CAP) because it relates to investment progress in a fund connected to the company’s capital activities. It is not a full report, earnings release, or regulatory filing. Therefore, the classification is CAP with high confidence.
2019-09-29 Chinese
关于控股股东部分股份补充质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the supplementary pledge of shares by a controlling shareholder. It details the number of shares pledged, the pledge period, the pledgee, and the risk assessment related to the pledge. There is no financial report, earnings data, or management discussion. The document is short (1189 characters) and serves as a disclosure of a specific shareholder's share pledge event. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share pledge details and risk, not a financial report or capital change announcement.
2019-09-27 Chinese
关于与黑龙江省科力高科技产业投资有限公司、李振国签订《战略合作框架协议》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a "Strategic Cooperation Framework Agreement" between the company and other parties. It explicitly states that the agreement is a framework and does not constitute a substantive cooperation commitment. The document includes details about the parties involved, the nature of the agreement, and risk warnings. It does not contain financial statements, audit information, or detailed financial results. The document is relatively short (2154 characters) and serves as a formal disclosure of a corporate event rather than a full report or detailed financial filing. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories.
2019-09-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.